novo glp-1 Nordisk launches Wegovy weight-loss pill in US, triggering price war | Pharmaceuticals industry Hims Inc. - Novo Nordisk's
Description
Journal of diabetes research
Exendin-4 prevented angiotensin II-induced hypertension in non-diabetic mice and inhibited angII-induced phosphorylation of ERK1/2 in cultured renal cells
Stateline reporter Shalina Chatlani can be reached at [email protected] .
Identifying patient subgroups that are most likely to benefit from GLP-1RAs based on these factors could improve treatment outcomes and minimize side effects
